FDA Releases Draft Guidance on Cannabis Research

The U.S. Food and Drug Administration (FDA) has announced the availability of draft guidance that “outlines FDA’s current thinking on several topics relevant to the development of cannabis and cannabis-derived products: The source of cannabis and cannabis-derived compounds for clinical research; general quality considerations for developing drugs that contain cannabis and cannabis-derived compounds; and calculation of percent delta-9 tetrahydrocannabinol (THC) in botanical raw materials, extracts, and finished products.” The agency will accept comments on the guidance until September 21, 2020.